Novo Nordisk is trading 3.1% up at DKK 329.75 as shares stage a modest rebound from recent weakness tied to disappointing 2026 guidance and obesity drug competition.
- The move appears to be a relief bounce as investors reassess an earlier selloff driven by downgraded 2026 sales and profit outlooks.
- Market sentiment remains focused on long-term concerns regarding U.S. pricing pressure on key obesity treatments and rising competition in the sector.
- The intraday gain comes without fresh company-specific news reported on July 15, 2026.